louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05092568: Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
Official title: Comparison of General Characteristics of Patients Diagnosed COVID-19 Positive Followed In Service
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Coronavirus Disease 2019
Vaccinia
Symptoms and Signs
Keywords: covid 19,
vaccine
covid pregnancy vaccine
Lead sponsor: Saglik Bilimleri Universitesi
Sponsor class: OTHER
First posted: 2021-10-25
Enrollment: 45
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant patients with positive COVID-19 test results, who were followed up and treated in the pandemic service of Çam and Sakura City Hospital.

Brief summary: comparison of general characteristics of patients diagnosed COVID-19 positive followed In service

Detailed description: After the explanation about the study is made, informed consent form will be obtained from the pregnant women who were hospitalized in the pandemic gynecology service (D block 10th floor pandemic obstetrics service) due to COVID-19 and who agreed to participate in the study. In our study, the clinical status of pregnant patients with COVID-19 positive test results, who were followed up and treated in the pandemic service in Basaksehir City Hospital, will be obtained by asking the patient about the symptoms and vaccination status in the patient follow-up form prepared in advance. Laboratory findings and imaging results ( CT/ anteroposterior X-ray) will be obtained from the recorded data.

Eligibility criteria: Inclusion Criteria: Pregnant patients positive COVID-19 test results followed up and treated in the pandemic service of Çam and Sakura City Hospital.

Exclusion Criteria: no exclusion criteria

-

Primary outcomes:
measure: Number of Participants
timeFrame: Two months
measure: Number of vaccinated participants
timeFrame: Two months
measure: Number of non-vaccinated Participants
timeFrame: Two months
measure: rate of non-vaccinated -vaccinated Participants
timeFrame: Two months
measure: rate of covid symptoms
timeFrame: Two months
measure: rate of inflammatory parameters
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
city: Başaksehir
country: Turkey
facility: Department of Obstetrics and Gynecology, Maternal-Fetal Medicine Unit, Başakşehir City Hospital, Hamidiye School of Medicine, University of Health Sciences,
state: İstanbul
Study officials:
affiliation: Saglik Bilimleri Universitesi
name: Ozge Ozdemir
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06584968: Improving the Application Skill of the Semmes-Weinstein Monofilament Test
Official title: Improving the Application Skill of Semmes-Weinstein Monofilament Test with Different Teaching Methods: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Training
Students
Lead sponsor: Hacettepe University
Sponsor class: OTHER
Collaborators: name: Çankırı Karatekin University
First posted: 2024-09-05
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The Semmes-Weinstein Monofilament Test is one of the most widely used and objective clinical tests for assessing the sense of touch. Some guides include standard instructions for the application of the Semmes-Weinstein Monofilament Test. With monofilaments applied correctly by the instructions, patients' threshold values can be determined accurately. However, there are disagreements about the accuracy of the pressure applied by the therapist who applies the monofilament to the patient. The investigators aimed to compare the application of the Semmes-Weinstein Monofilament Test to undergraduate students of the occupational therapy department by teaching it using classical methods and visual feedback.


Eligibility criteria: Inclusion Criteria:

* Being third or fourth-year undergraduate students of the Occupational Therapy Department
* Completing the Hand Rehabilitation course
* Being a volunteer to participate in the study

Primary outcomes:
measure: Application duration of the Semmes-Weinstein Monofilament Test
timeFrame: just before the intervention and just after completion of the intervention
measure: The applied force of the Semmes-Weinstein Monofilament Test
timeFrame: just before the intervention and just after completion of the intervention
measure: Intervals between the Semmes-Weinstein Monofilament Test applications
timeFrame: just before the intervention and just after completion of the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
Study officials:
References:
Clinical trial NCT01687868: Evaluation of Efficacy and Safety of General Anesthesia Using Dexmedetomidine With Sevoflurane in Patients Undergoing Arthroscopic Shoulder Surgery: Preliminary Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arthroscopic Shoulder Surgery in the Beach-chair Position
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2012-09-19
Enrollment: 19
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Patients undergoing shoulder arthroscopy in the beach chair position may be at risk for adverse neurologic events due to cerebral ischemia.

Dexmedetomidine, a potent alpha adrenoceptor agonist which dose-dependently reduces arterial blood pressure and heart rate, decreases the hemodynamic and catecholamine response in the perioperative period.

dexmedetomidine has an effect of peripheral vasoconstriction thus it is theologically appropriate for reducing bleeding for arthroscopic operation field.

The aim of this study is to evaluate the efficacy and the safety of dexmedetomidine on cerebral oxygen saturation, cognitive function, hemodynamic stability and operative field in patients undergoing arthroscopic shoulder surgery in the beach-chair position.


Eligibility criteria: Inclusion Criteria:

* ASA I-II
* Aged between 20 and 70 year
* general anesthesia for arthroscopic shoulder surgery in the beach-chair position

Exclusion Criteria:

* Congestive heart failure, coronary artery occlusive disease
* Bradycardia \< 50 BPM, 2nd degree \< AV block
* Poorly controlled hypertension
* ß blocker medication
* Coagulopathy
* Pregnancy, nursing

Primary outcomes:
measure: Regional cerebral oxygen saturation value
timeFrame: T1,T2,T3, T4, T5,T6, T7, T8, T9 time of post-dose during surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine,Yonsei University Health System
Study officials:
References:
Clinical trial NCT00884468: Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
Official title: Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriatic Arthritis
Keywords: Anxiety and depression in patients with psoriatic arthritis
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2009-04-20
Enrollment: 384
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with PsA from outpatient's surgery or primary health care centres

Brief summary: This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.


Eligibility criteria: Inclusion criteria:

* Patients both genders over 18 years old
* Patients with PsA diagnosis

Exclusion criteria:

* Patients with PsA that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study.
* Patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol.
* Patients that in the study period are taking part in another clinical trial.

Primary outcomes:
measure: Prevalence of anxiety and/or depression disorders in patients suffering from PsA in Spain as measured by the Hospital Anxiety and Depression Scale (HAD)
timeFrame: 12 months
Secondary outcomes:
measure: To assess the relation between the PsA severity and the presence of anxiety and/or depression disorders in patients suffering from PsA in Spain.
timeFrame: 12 months
Other outcomes:
Locations:
city: Reus
country: Spain
state: Tarragona
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01170468: Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals
Official title: Does Vitamin D Reduce Risk of Developing Type II DM in Prediabetics? A Double Blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Keywords: Prediabetics
DM
vitamin D
Lead sponsor: King Faisal Specialist Hospital & Research Center
Sponsor class: OTHER
First posted: 2010-07-27
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Both vitamin D deficiency and type II DM/prediabetes are highly prevalent. Vitamin D status has been negatively associated with the presence of type II DM and glycemic control. A cause-effect relationship between vitamin D deficiency and the development of type II DM has not been established.

The investigators plan to conduct a 2 year, double blind, randomized, placebo controlled trial on the effect of vitamin D3 supplement on the incidence of type II DM in high risk individuals.


Eligibility criteria: Inclusion Criteria:

* Adults living in Riyadh area with impaired fasting glucose or/and impaired glucose tolerance (prediabetics) and total 25 OH vitamin D level between 10-30 nmol/l
* Who consume no more than one serving of milk/day
* Do not take vitamin supplement
* Habitually have less than 10 hour of sun exposure per week
* Don't suffer from granulomatus conditions, liver disease, kidney disease, or diabetes
* Don't take anticonvulsants, barbiturates, steroids, or antidiabetic medications.

Primary outcomes:
measure: The incidence of DM
timeFrame: 2 years
Secondary outcomes:
measure: slope of fasting glucose level
timeFrame: 2 years
measure: slope of 2-hour post challenge glucose level
timeFrame: 2 years
measure: area under the curve of BP
timeFrame: 2 years
measure: area under the curve of weight
timeFrame: 2 years
measure: area under the curve of 25 OH vitamin D level
timeFrame: 2 years
measure: fasting insulin to glucose ratio
timeFrame: 2 years
measure: incidence of hypercalcemia
timeFrame: 2 years
measure: incidence of hypercalciuria
timeFrame: 2 years
measure: time to develop DM
timeFrame: 2 years
Other outcomes:
Locations:
city: Riyadh
country: Saudi Arabia
facility: King Faisal Specialist Hospital & Research Center
Study officials:
affiliation: King Faisal Specialist Hospital & Research Center
name: Muhammad M Hammami, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04818268: Sensory Memory in Speech Motor Learning
Official title: Role of Sensory Working Memory in Speech Motor Learning Aim 2
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Speech
Consolidation
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Deafness and Other Communication Disorders (NIDCD)
First posted: 2021-03-26
Enrollment: 120
Sex: ALL
Minimum age (years): 21
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The proposed studies focus on memory for speech movements and sounds and its relation to learning. Continuous theta-burst transcranial magnetic stimulation (cTBS) will be used to suppress activity in a region of pre-frontal cortex associated with somatic and auditory working memory (Brodmann area 46v) to test its involvement in learning.

Detailed description: This study will assess the relationship between sensory working memory and speech motor adaptation using a between subjects design. Participants will be assigned to one of two groups. Each group will undergo both auditory and somatosensory working memory tests. This will be followed by adaptation to altered auditory feedback. Using a different group of subjects, cTBS will be used to disrupt neural activity in Brodmann area 46v in ventrolateral prefrontal cortex to test its involvement in adaptation. One set of tests will focus on the effects of cTBS on both auditory and somatosensory working memory. A second set of tests will focus on the effects of cTBS on speech motor adaptation to altered auditory feedback. Both working memory and adaptation are assessed on 0 to 100 scales.

Eligibility criteria: Inclusion Criteria:

* right handed adults
* no known physical or neurological abnormalities

Exclusion Criteria:

* patients with:
* cardiac pacemaker
* surgical clips or values on the heart
* implants
* metal or metallic fragments in any part of the body
* pregnancy
* claustrophobia
* a personal or family history of epilepsy
* currently taking antipsychotic drugs
* currently taking antidepressant drugs
* currently taking antianxiety drugs
* history of concussion.

Primary outcomes:
measure: Speech Motor Learning
timeFrame: Performance as measured at the end of learning (single day experiment)
measure: Sensory Memory
timeFrame: Single day experiment
Secondary outcomes:
Other outcomes:
Locations:
city: Montréal
country: Canada
facility: McGill University
state: Quebec
Study officials:
affiliation: Haskins Laboratories
name: David Ostry
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00699868: Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) Patients
Official title: Cellular Immunity, Cytomegalovirus Infection and Septic Shock in ICU Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cytomegalovirus Infection
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2008-06-18
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL

Brief summary: This prospective study evaluate the immune status of patients admitted in ICU.CMV remains dormant in the body, but in people with immune deficiency, CMV could reactivate and cause life-threatening pneumonia.

Detailed description: Candidates will be screened with medical history and blood tests.Then, 2 groups of 20 patients (with or without CMV reactivation) matched for CMV status will be compared for their immune system against CMV.

Eligibility criteria: Inclusion Criteria:

* Age more than 18-year-old
* Informed consent

Exclusion Criteria:

* minors,
* pregnant or lactating women,
* adults under guardianship,
* immunosuppression at the entrance to resuscitation,
* AIDS

Primary outcomes:
measure: Bring to light the quantitative and qualitative immunological modifications of the present cells NK before the arisen of an infection to CMV
timeFrame: 24 months
Secondary outcomes:
measure: Bring to light the quantitative and qualitative immunological modifications of cells NK in the consequences of an infectious shock
timeFrame: 24 months
Other outcomes:
Locations:
city: Marseille
country: France
facility: Hôpital de Sainte Marguerite- Service de Réanimation Médicale
Study officials:
affiliation: Assistance Publique des Hôpitaux de Marseille
name: Jean-Marie FOREL, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Matta J, Baratin M, Chiche L, Forel JM, Cognet C, Thomas G, Farnarier C, Piperoglou C, Papazian L, Chaussabel D, Ugolini S, Vely F, Vivier E. Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood. 2013 Jul 18;122(3):394-404. doi: 10.1182/blood-2013-01-481705. Epub 2013 May 17.
citation: Forel JM, Chiche L, Thomas G, Mancini J, Farnarier C, Cognet C, Guervilly C, Daumas A, Vely F, Xeridat F, Vivier E, Papazian L. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS One. 2012;7(12):e50446. doi: 10.1371/journal.pone.0050446. Epub 2012 Dec 6.
Clinical trial NCT01604668: Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring
Official title: Comparative Accuracy of Three Versions of Non-Invasive Hemoglobin Monitoring.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blood Loss
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2012-05-24
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing spine surgery

Brief summary: There is no study hypothesis. The purpose of this study is to compare the accuracy of the: 1) SpHb (Radical 7 Pulse Co-Oximetry with SpHb™) RevF sensor (currently marketed), 2) the SpHb RevG sensor (a new, limited release version), and 3) the Pronto-7 sensor (currently marketed version) in patients undergoing spine surgery.

Detailed description: The purpose of this study is to compare the accuracy of the: 1) SpHb RevF sensor (currently marketed), 2) the SpHb RevG sensor (a new, limited release version), and 3) the Pronto-7 sensor (currently marketed version) in patients undergoing spine surgery. The results from the three sensors will be compared to a blood hemoglobin level taken intermittently (as a function of the patient's anesthesia care) and analyzed in the UCSF Clinical Laboratories.

This is an observational study.

Eligibility criteria: Inclusion Criteria:

* ≥ 18 years of age
* ASA Classification 1, 2 or 3
* Scheduled to undergo spine surgery

Exclusion Criteria:

* Pregnant of nursing
* In the investigator's judgement would not be suitable for research

Primary outcomes:
measure: Comparison of hemoglobin levels derived by sensor RevF versus sensor RevG versus a hemoglobin derived from a blood sample. A baseline hemoglobin level will be taken from the Pronto-7 hand-held hemoglobin device prior to surgery.
timeFrame: Two or more measurements during surgery
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California, San Francisco Moffitt/Long Hospitals
state: California
Study officials:
affiliation: University of California, San Francisco
name: Ronald D. Miller, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Miller RD, Ward TA, Shiboski SC, Cohen NH. A comparison of three methods of hemoglobin monitoring in patients undergoing spine surgery. Anesth Analg. 2011 Apr;112(4):858-63. doi: 10.1213/ANE.0b013e31820eecd1. Epub 2011 Mar 8.
Clinical trial NCT05860868: Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
Official title: Two Cycles VS Three Cycles Induction Chemotherapy Plus Concurrent Chemoradiotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Locally Advanced Nasopharyngeal Carcinoma
Lead sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2023-05-16
Enrollment: 474
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

1. Age 18-65 years old;
2. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma;
3. Stage T3-4N0-1 (according to the UICC/AJCC 8th);
4. No distant metastasis;
5. Have not received anti-cancer treatment in the past;
6. ECOG (Eastern Cooperative Oncology Group of the United States): 0-1;
7. Adequate hematologic, hepatic and renal function.

Exclusion Criteria:

1. The purpose of treatment is palliative;
2. Diagnosed with other malignant tumors at the same time;
3. Malignant tumor history;
4. Pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period;
5. Combined serious illness.

Primary outcomes:
measure: FFS, Failure Free Survival
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: First Affiliated Hospital, Sun Yat-Sen University
state: Other (Non U.s.)
Study officials:
References:
Clinical trial NCT03947268: Radiotherapy in Palliation of Advanced Pelvic Cancer
Official title: Palliative Short-course Radiotherapy in Advanced Pelvic Cancer: a Phase II Study (SHARON Project)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palliative Care
Keywords: palliative care
pelvic cancer
radiotherapy
pain
Quality of life
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2019-05-13
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study wants to define the safety and efficacy of a short-course radiation therapy in patients with symptomatic advanced pelvic cancer.

Detailed description: he study wants to define the safety and efficacy of a short course accelerated radiation therapy delivered in twice daily fractions and 2 consecutive days for symptomatic palliation of advanced solid cancer.

Eligibility criteria: Inclusion Criteria:

* histologically proven advanced pelvic cancer
* excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status
* age \> 18 years
* Eastern Cooperative Oncology Group (ECOG) \<3

Exclusion Criteria:

- prior radiotherapy to the same region

Primary outcomes:
measure: Assessment of symptoms [pain]
timeFrame: 1 year]
Secondary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Acute radiation toxicity]
timeFrame: 1 year
measure: Incidence of Treatment-Emergent Adverse Events [Late radiation toxicity]
timeFrame: 1 year
measure: Assessment of the Quality of life (QOL)
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Radiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna, Italy
name: Alessio G. Morganti, MD
role: PRINCIPAL_INVESTIGATOR
References: